

PRESS RELEASE

Boston Biochem and UbiQ to collaborate on di-Ubiquitin chains

Cambridge, USA / Amsterdam, the Netherlands, 10th December 2010

Boston Biochem and UbiQ are entering into a collaboration to offer unique di-Ubiquitin chains to the scientific community, to enable ubiquitin-related research and drug discovery.

Ubiquitin modification regulates most aspects of cell life. Both the type and number of poly-ubiquitin chains, conjugated to a protein target, regulate distinct signals that affect physiological processes. Poly-ubiquitin chains are built by forming an isopeptide bond between the C-terminus of one ubiquitin and one of the seven potential lysines (K6, K11, K27, K29, K33, K48 or K63) of the preceding ubiquitin.

“Until now, the lack of access to the complete set of these different linkages severely limited research. By combining Boston Biochem’s experience and solid reputation in the ubiquitin field with UbiQ’s scientific expertise and its proprietary technology platform, we are the first to generate purified ubiquitin chains of all linkages”, says Francesco Melandri, CEO of Boston Biochem. “We are very pleased to collaborate with Boston Biochem,” says Alfred Nijkerk, CEO of UbiQ, “with these tools we can accelerate the discovery of novel enzymes, substrates and ultimately drug therapies”. UbiQ CSO and Netherlands Cancer Institute (NKI) investigator Huib Ovaa explains: “Ubiquitin research should not be limited to K48 and K63 chains simply because that is all that is available. From now on we can basically synthesize anything needed to move this field to the next level.”

About BBI

Boston Biochem, Inc. is the world’s leading producer of Ubiquitin Proteasome Pathway products. Since our founding in 1997, it has been our mission to facilitate and accelerate research and drug discovery. All of our specialized reagents are developed, produced and characterized in-house with a commitment to quality and affordability. We provide personalized and knowledgeable customer service and technical services to support our product line.

About UbiQ

UbiQ was founded in 2010 as a spin-out of the Netherlands Cancer Institute (NKI). We develop and commercialise well defined ubiquitinated peptides and conjugates, that will enable drug discovery in the rapidly expanding ubiquitin-based field. Our products are targeted at pharmaceutical companies and academic research labs. Next to our reagent and assay business, we will initiate our own drug discovery and development efforts together with pharma partners in the near future.

Contact

Francesco D. Melandri, CEO

Phone: +1 617 241 7072

Email: fmelandri@bostonbiochem.com

Boston Biochem Inc

840 Memorial Drive

Cambridge, MA 02139, USA

www.bostonbiochem.com

Alfred N. Nijkerk, CEO

Phone: +31 6 5512 8387

Email: alfrednijkerk@ubiqbio.com

UbiQ Bio BV

Henriette Bosmansstraat 11

1077 XE, Amsterdam, the Netherlands

www.ubiqbio.com